Printer Friendly

Cell therapy for multiple sclerosis patients getting closer.

NEW YORK, N.Y., July 24, 2014 -- Scientists here are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient's own cells.

For the first time, scientists at the New York Stem Cell Foundation (NYSCF) Research Institute generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis.

They also developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system, distinguished by recurrent episodes of demyelination and the consequent neurological symptoms.

Primary progressive multiple sclerosis is the most severe form of multiple sclerosis, characterized by a steady neurological decline from the onset of the disease.

There are no effective treatments or cures for primary progressive multiple sclerosis and treatments relies merely on symptom management.

Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research.

This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.

Stem cell lines and oligodendrocytes allow researchers to "turn back the clock" and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed.

The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.

"We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases," said Susan Solomon of the NYSCF.

"We believe that this protocol will help the MS field and the larger scientific community to better understand human oligodendrocyte biology and the process of myelination. This is the first step towards very exciting studies: the ability to generate human oligodendrocytes in large amounts will serve as an unprecedented tool for developing remyelinating strategics and the study of patient-specific cells may shed light on intrinsic pathogenic mechanisms that lead to progressive MS." said Valentina Fossati, an NYSCF investigator.

In multiple sclerosis, the protective covering of axons, called myelin, becomes damaged and lost.

In this study, the scientists not only improved the protocol for making the myelin-forming cells but they showed that the oligodendrocytes derived from the skin of primary progressive patients are functional, and therefore able to form their own myelin when put into a mouse model.

This is an initial step towards developing future autologous cell transplantation therapies in multiple sclerosis patients

The advance opens up critical new avenues of research to study multiple sclerosis and other diseases.

Oligodendrocytes are implicated in many different disorders, therefore this research not only moves multiple sclerosis research forward, it allows scientists the ability to study all dcmyclinating and central nervous system disorders.

Oligodendrocytes are increasingly recognized as having an absolutely essential role in the function of the normal nervous system, as well as in the setting of neurodegenerative diseases, such as multiple sclerosis.

"The new work will help to improve our understanding of these important cells. In addition, being able to generate large numbers of patient-specific oligodendrocytes will support both cell transplantation therapeutics for demyelinating diseases and the identification of new classes of drugs to treat such disorders," said Lee Rubin of the Harvard Stem Cell Institute.

Contact: http://www.nyscf.org/
COPYRIGHT 2014 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Advanced Stem Cell Technology
Publication:Stem Cell Business News
Date:Aug 11, 2014
Words:600
Previous Article:First IPS cells created to offer human model of insulin resistance.
Next Article:"Naive" pluripotent human embryonic stem cells created.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters